Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201

Antibody-Drug Conjugates (ADCs) have a tripartite structure: Antibody-Linker-Payload. Currently, 272 ADCs are in clinical trials worldwide. Despite the withdrawal of Belantamab mafodotin, 14 ADCs remain on the market. ADC development is highly competitive, with strategic patent deployment being critical. For example, DS-8201's patents on each component offer primary protection, while novel combinations and pharmacological properties drive patent iteration and extend market exclusivity. Comprehensive extraction and aggregation of these source, core, and iterative patents are essential for high-quality patent research reports to guide infringement analysis, biosimilar development, and investment strategies. This report focuses on ADC patent searches, using DS-8201 as a case study to outline the research process and map the latest patent landscapes in China and the United States.